New weekly shot could simplify diabetes care for millions
NCT ID NCT07055386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental injections, GZR102 (once a week) and GZR18 (every two weeks), in adults with type 2 diabetes whose blood sugar is not well controlled on current GLP-1 medications. About 90 Chinese participants will receive one of the two treatments to see which works better at lowering blood sugar and weight, and to check for side effects. The goal is to find a more convenient option for managing diabetes long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site 01
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your gut bacteria hold the key to protecting your kidneys?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can diabetes disrupt the Brain-Heart link?
- A scent of citrus: could bitter orange oil ease fatigue and aid sleep in diabetes?
- Gut bacteria swap may tame diabetes and thyroid disease
- A blood marker may reveal how well diabetes treatments are working